Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2018³â Á¦34Â÷ Workshop °³ÃÖ
"Boost pharma R&D productivity through open innovation"
2018³â 10¿ù 25ÀÏ(¸ñ) ~ 26ÀÏ(±Ý) / °ïÁö¾Ï ¸®Á¶Æ® Grand Ballroom
1. ±Í»çÀÇ ¹«±ÃÇÑ ¹ßÀü°ú ±ÍÇÏÀÇ °Ç½ÂÇϽÉÀ» ±â¿øÇÕ´Ï´Ù.
2. Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸¿¡¼´Â Á¦34Â÷ ¿öÅ©¼¥À» ¡°Boost pharma R&D productivity through open innovation" À̶ó´Â ÁÖÁ¦·Î ´ÙÀ½°ú °°ÀÌ °³ÃÖÇÏ¿À´Ï, ȸ¿ø ¿©·¯ºÐÀÇ ¸¹Àº Âü¿© ¹Ù¶ø´Ï´Ù. |
¡á Çà»ç°³¿ä
Çà»ç¸í |
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2018³â Á¦34Â÷ Workshop |
ÁÖÁ¦ |
Boost pharma R&D productivity through open innovation |
ÀϽà |
2018³â 10¿ù 25ÀÏ(¸ñ) 12:00 ~ 26ÀÏ(±Ý) 15:00 |
Àå¼Ò |
°ïÁö¾Ï¸®Á¶Æ® Grand Ballroom (EWºô¸®Áö B2) ÀÚ¼¼È÷ º¸±â
ÁÖ¼Ò : °æ±âµµ ±¤Áֽà µµÃ´¸é µµÃ´À·Î 278
|
»çÀüµî·Ï |
2018³â 9¿ù 17ÀÏ (¿ù) ~ 10¿ù 12ÀÏ (±Ý) |
»çÀüµî·Ï±â°£ |
2018³â 9¿ù 17ÀÏ (¿ù) ~ 10¿ù 12ÀÏ (±Ý)
1) ȨÆäÀÌÁö (www.nonclinical.or.kr)³» Á¦34Â÷ ¿öÅ©¼¥ »çÀüµî·Ï ¸Þ´º ÀÌ¿ë
2) ºñȸ¿øÀº ȸ¿ø°¡ÀÔ ÈÄ µî·Ï °¡´É
|
µî·Ïºñ |
»çÀüµî·Ï 10¸¸¿ø(Çлý 6¸¸¿ø), ÇöÀåµî·Ï 15¸¸¿ø(Çлý 10¸¸¿ø)
1) »çÀüµî·Ï Ä«µå°áÁ¦ °¡´É.(Ä«µå°áÁ¦ ½Ã ¼¼±Ý°è»ê¼ ¹ßÇàºÒ°¡)
2) ÀÚ·áÁý, ¼ö·áÁõ, ¼÷¹Ú (4~5ÀÎ/1½Ç), 25ÀÏ Áᫎ ¹× ¼®½Ä, 26ÀÏ Á¶½Ä ¹× Áᫎ Æ÷ÇÔ
3) ¼¼±Ý°è»ê¼ ¹ß±Þ (ÀÔ±ÝÀÏ ±âÁØ 1ȸ ¹ß±Þ)ÀÌ ÇÊ¿äÇϽŠºÐÀº »ç¾÷ÀÚµî·ÏÁõ ÷ºÎ ¿ä¸Á
4) ÇöÀåµî·ÏÀÇ °æ¿ì, ¼¼±Ý°è»ê¼ ¹ß±Þ ºÒ°¡, ¿¬±¸È¸ ÀÚü ¿µ¼öÁõ ¹ß±Þ
5) ÀԱݰèÁ : ¿ì¸®ÀºÇà 1005-403-436526 ¢ßµå¸²ÆÄÆ®³Ê Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸
6) ÀԱݸ¶°¨ : 2018³â 10¿ù 12ÀÏ(±Ý), ÀÔ±Ý ½Ã ¼Ò¼Ó, ¼º¸í ±âÀÔ ¿ä¸Á |
¹®ÀÇ |
±âŸ ¹®ÀÇ»çÇ×Àº Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ »ç¹«±¹À¸·Î ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
KSNS »ç¹«±¹ : Tel. 031-702-9123 / E-mail. ksns@nonclinical.or.kr / ´ã´çÀÚ. ±èÁذï
|
º°Ã· |
[°ø¹®] KSNS 34Â÷ ¿öÅ©¼¥ °³ÃÖ ¾È³»
[¾È³»] KSNS 34Â÷ ¿öÅ©¼¥ ¸®Ç÷¿
|
¡á µî·Ï¾È³»
- »çÀüµî·Ï ¾È³»
µî·Ï±â°£ |
2018³â 9¿ù 17ÀÏ (¿ù) ~ 10¿ù 12ÀÏ (±Ý) |
µî·Ï¹æ¹ý |
- ¿¬±¸È¸ ȨÆäÀÌÁö (www.nonclinical.or.kr) ÇмúÇà»ç >»çÀüµî·Ï ¸Þ´º ÀÌ¿ë
- ºñȸ¿øÀº ȸ¿ø°¡ÀÔ ÈÄ, »çÀüµî·ÏÀÌ °¡´ÉÇÕ´Ï´Ù.
|
- µî·Ïºñ <Áß¿ä°øÁö >Ä«µå°áÁ¦ °¡´É
µî·Ïºñ ±¸ºÐ |
»çÀüµî·Ï |
ÇöÀåµî·Ï |
Á¤È¸¿ø |
100,000¿ø |
150,000¿ø |
Çлýȸ¿ø |
60,000¿ø |
100,000¿ø |
• »çÀüµî·Ïºñ : ÀÚ·áÁý, ¼ö·áÁõ, ¼÷¹Ú (4~5ÀÎ/1½Ç), 25ÀÏ Áᫎ ¹× ¼®½Ä, 26ÀÏ Á¶½Ä ¹× Áᫎ Æ÷ÇÔ
• ¼¼±Ý°è»ê¼ ¹ß±Þ(ÀÔ±ÝÀÏ ±âÁØ 1ȸ ¹ß±Þ)ÀÌ ÇÊ¿äÇÒ °æ¿ì, ¿Â¶óÀÎ µî·Ï¶§ ¼¼±Ý°è»ê¼ ¹ßÇàÇà¿©ºÎ¸¦ üũÇϰí, »ç¾÷ÀÚµî·ÏÁõ »çº»À» ¹Ýµå½Ã ÷ºÎ
• ÇöÀåµî·Ï ¹× Çлýµî·ÏÀÇ °æ¿ì, ¼¼±Ý°è»ê¼ ¹ß±Þ ºÒ°¡, ¿¬±¸È¸ ÀÚü ¿µ¼öÁõ ¹ß±Þ |
- ¹«ÅëÀåÀÔ±Ý (°èÁÂÀÌü)
ÀԱݰèÁ |
¿ì¸®ÀºÇà 1005-403-436526 ¢ßµå¸²ÆÄÆ®³Ê Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ |
ÀԱݰèÁ |
~ 2018³â 10¿ù 12ÀÏ (±Ý) 18½Ã ±îÁö |
• ÀԱݽà ¹Ýµå½Ã "¼Ò¼Ó/¼º¸í" À» ±âÀÔÇϼ¼¿ä.
• ¹«ÅëÀå ÀÔ±Ý(°èÁÂÀÌü)ÀÌü ÈÄ, »ç¹«±¹¿¡¼ ÀÔ±ÝÀ» È®ÀÎÇÏ´Â ½Ã°£ÀÌ ÇÊ¿ä ÇÕ´Ï´Ù.
• ±âŸ µî·Ï °ü·Ã ¹®ÀÇ»çÇ×Àº Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ »ç¹«±¹À¸·Î ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
TEL. 031-702-9123 / E-mail. ksns@nonclinical.or.kr, ±èÁذï
|
¡á ÇÁ·Î±×·¥ ¾È³»
- ÀϽà : 2018³â 10¿ù 25ÀÏ(¸ñ) 12:00 ~ 26ÀÏ(±Ý) 15:00
- Àå¼Ò : °ïÁö¾Ï¸®Á¶Æ® Grand Ballroom (EWºô¸®Áö B2)
- ÁÖÁ¦ : Boost pharma R&D productivity through open innovation
|
Day 1 |
10¿ù 25ÀÏ (¸ñ) |
½Ã°£ |
ÇÁ·Î±×·¥ |
12:00~13:00 |
µî·Ï ¹× Á¡½Ä ½Ä»ç |
13:00~13:10 |
°³È¸»ç (¿À¼¼¿õ ȸÀå) |
Session 1 |
Plenary talk |
13:10~13:50 |
Success factors in drug discovery and development (º¸·ÉÁ¦¾à, ±è´ÞÇö) |
13:50~14:30 |
½Å¾à°³¹ß¿¡ ÀÖ¾î¼ º¥Ã³Ä³ÇÇÅ»ÀÇ ¿ªÇÒ (¿¡ÀÌÆ¼³Ñ, °û»óÈÆ) |
Session 2 |
Platform |
14:30~15:10 |
Discovering New Drug Target through Systemic KO Mouse Phenotyping (¼¿ï´ë, ¼ºÁ¦°æ) |
15:10~15:50 |
Protac-induced protein degradation for the next small molecule drug discovery (Çѱ¹ÈÇבּ¸¿ø, ȲÁ¾¿¬) |
15:50~16:20 |
Booth exhibition & Coffee break |
Session 3 |
Case study 1 |
16:20~17:00 |
Nonclinical Studies for Human Clinical Trials of Gene Therapy : case studies of VM202 and VM206 (¹ÙÀÌ¿À¸Þµå, Á¤Àç±Õ) |
17:00~17:40 |
JW1601, an orally available histamine H4 receptor inverse agonist, with anti-pruritic & anti-inflammatory dual effect as a treatment for atopic dermatitis (JWÁß¿ÜÁ¦¾à, È£Çʼö) |
18:30~21:00 |
ÃÑȸ & Social networking |
Day 2 |
10¿ù 26ÀÏ (±Ý) |
½Ã°£ |
ÇÁ·Î±×·¥ |
07:00~09:00 |
¾ÆÄ§ ½Ä»ç |
Session 4 |
¾àÈ¿ºÐ°ú |
µ¶¼ººÐ°ú |
¾àµ¿ºÐ°ú |
09:00~09:40 |
Supporting Chemistry with Big Data : CognitiveIT technologies (OntoChem, Dr.Michael Ahrweiler) |
»ê¾÷ÈÇй°ÁúÀÇ ÈíÀÔµ¶¼º¿¬±¸(»ê¾÷¾ÈÀüº¸°Ç¿¬±¸¿ø, ±è¿ë¼ø) |
Strategies to determine the target human metabolites using radiolabeled compounds - Example from non-clinical to clinical (Axcelead, Fumihiro Jinno) |
09:40~10:20 |
BIONEER'S Novel RNAi Drug Platform SAMiRNA¢â (¹ÙÀÌ¿À´Ï¾î, À±Æò¿À) |
SEND¿Í ºñÀÓ»ó½ÃÇèÀÚ·áÀÇ Ç¥ÁØÈ (¾ÈÀü¼ºÆò°¡¿¬±¸¼Ò, ÀÓ¿ÏÁß) |
Preclinical PK of 2 NCEs for IND Submission (Ãæ³²´ë, ±¸Å¼º) |
10:20~10:40 |
Booth exhibition & Coffee break |
10:40~11:20 |
Age-related Clonal Hematopoiesis: A Novel Target for Disease Treatment (Áö³ð ¿ÀÇǴϾð, ÀÓÈ£±Õ) |
ºñÀÓ»ó ½ÃÇè °ü¸® ±ÔÁ¤ º¯°æ¿¡ µû¸¥ ÇØ¼³¼ °³Á¤¿¬±¸ (°Ç¾ç´ë, ȲÁø¾Æ) |
2018 FDA MV Guidance: Key Changes and Considerations (³ì½ÊÀÚÀÇ·áÀç´Ü, ÀÌÈñÁÖ) |
11:20~12:00 |
Anti-diabetic effects of novel PTP1B inhibitors isolated from Stereocaulon alpinum (¼º±Õ°ü´ë, Á¶µ¿±Ô) |
´ëüµ¶¼º½ÃÇè°ú GLP À̽´ (ÄÍ¿Â, ¿ÀÁ¤ÀÚ) |
Major Changes in Current FDA Guideline for In-vitro Drug-Drug Interaction Studies (À¯ÇѾçÇà, ±èµ¿±Õ) |
12:00~13:30 |
Luncheon seminar & Booth exhibition |
Session 5 |
Case study 2 |
13:30~14:10 |
Challenges and Strategies of Biosimilar Clinical Development (»ï¼º¹ÙÀÌ¿À·ÎÁ÷½º, Á¤Áø¾Æ) |
14:10~14:50 |
Open Innovation: Strategy & Cases (À¯ÇѾçÇà, ¿À¼¼¿õ) |
14:50~15:00 |
Æóȸ»ç ¹× °æÇ° Ãß÷ (ºÎȸÀå, ½ÉÇöÁÖ) |
* »ó±â ÇÁ·Î±×·¥Àº ¿¬ÀÚ ¹× ±âŸ »çÁ¤À¸·Î º¯µ¿ ¼ö ÀÖ½À´Ï´Ù.
¡á ¿À½Ã´Â ±æ
ÁÖ¼Ò |
°æ±âµµ ±¤Áֽà µµÃ´¸é µµÃ´À·Î 278, EWºô¸®Áö B2 |
ȨÆäÀÌÁö |
°ïÁö¾Ï ¸®Á¶Æ® (°æ±âµµ ±¤ÁÖ) ÀÚ¼¼È÷ º¸±â
|
 |
ÁÖÂ÷ |
¸®Á¶Æ® ³» EWºô¸®Áö/Lºô¸®Áö ÁöÇÏ ÁÖÂ÷Àå, 5~7¹ø ÁÖÂ÷ÀåÀº Åõ¼÷°´(»çÀü¿¹¾àÁ¦)À» À§ÇÑ
ÁÖÂ÷ÀåÀÔ´Ï´Ù. |
´ëÁß±³Åë |
[ ÁöÇÏö/Àüö ÀÌ¿ë½Ã ]
- °ïÁö¾Ï Àüö¿ª ÇÏÂ÷ ÈÄ Åýà ¹× ¼øÈ¯¹ö½º ÀÌ¿ë
- °ïÁö¾Ï Àüö¿ª ¼øÈ¯¹ö½º ¿îÇà
¡Ø ¼øÈ¯¹ö½º(45ÀνÂ/1½Ã°£ °£°Ý ¿îÇà/ÀÔ¼® Á¦ÇÑ) > Åýà ÀÌ¿ë ±ÇÀå
[ ±¤¿ª¹ö½º ÀÌ¿ë ½Ã ] (1113-1, 500-1, 500-2)
- °ïÁö¾Ï Å͹̳ΠÇÏÂ÷ ÈÄ Åýà ¹× ¼øÈ¯¹ö½º ÀÌ¿ë
- °ïÁö¾Ï Å͹̳Π¼øÈ¯¹ö½º ¿îÇà
¡Ø ¼øÈ¯¹ö½º(45ÀνÂ/1½Ã°£ °£°Ý ¿îÇà/ÀÔ¼® Á¦ÇÑ) > Åýà ÀÌ¿ë ±ÇÀå |
¼øÈ¯¹ö½º |
°ïÁö¾Ï ¡ç¡æ ¸®Á¶Æ® ¿îÇà ¼øÈ¯¹ö½º (45ÀνÂ/ÀÔ¼® Á¦ÇÑ)
- °ïÁö¾ÏÅ͹̳Πž½ÂÀå¼Ò : °ïÁö¾ÏÅ͹̳Π¸ÂÀºÆí ´Ù¼Ö¾à±¹ ¾Õ
- °ïÁö¾Ï¸®Á¶Æ® ž½ÂÀå¼Ò : 4¹ø ÁÖÂ÷Ÿ¿ö µÞÆí
- °ïÁö¾Ï Àüö¿ª ž½ÂÀå¼Ò : °ïÁö¾ÏÀüö¿ª Kiss&Ride ž½ÂÀå |
|